Phase 2b data from EASD 2026 show the amylin-incretin combination also cut HbA1c by up to 2.9% in adults with obesity or overweight and type 2 diabetes.
|Videos|November 3, 2021
Support Services Are Essential For Neuroendocrine Tumor Treatment in Large Cancer Centers
Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, discusses what kind of support services at large cancer centers can help individuals with neuroendocrine tumors with their treatment.
Advertisement
In a Pharmacy Times® interview, Nicole Ross, MSN, CRNP, AOCNP, nurse practitioner for the department of hematology/oncology at Fox Chase Cancer Center, about her presentation on neuroendocrine tumor (NETs) management in large cancer centers at the NANETS 2021 Conference.
She discussed what kind of support services at large cancer centers can help individuals with NETs with their treatment.
Advertisement
Related to this article
fMRI data show cagrilintide-semaglutide altered brain responses to high-calorie food cues; REIMAGINE analyses point to ectopic fat and bone effects.
A Novo Nordisk–funded claims analysis of adults with type 2 diabetes found an adjusted HR of 1.06 for MACE with switching, although the findings cannot show causation.
A new analysis finds a significant weight loss edge for tirzepatide under one estimand but not another; no head-to-head trial exists at these doses.
Indirect comparison links orforglipron 17.2 mg to 1.5% more weight loss and 0.3% more A1C lowering than oral semaglutide 25 mg in adults with type 2 diabetes.
Phase 3 TRIUMPH-2 data presented at EASD show HbA1C reductions up to 1.6%, with GI effects, hypotension, and dysesthesia as key counseling points.
Phase 2 MILESTONE results suggest that postinduction minimal residual disease (MRD) negativity can identify a small subset of transplant-eligible patients with newly diagnosed multiple myeloma who may defer autologous stem cell transplantation.
A phase 3 trial shows etentamig boosts response and delays progression in triple-class exposed RRMM.
Advertisement
Advertisement
Trending on Pharmacy Times
1
Pharmacists Key to Lp(a) Counseling and Lipid Optimization
2
EloraTZP Delivers Up to 23.3% Weight Loss in Adults With Obesity and T2D
3
Why Lp(a) Testing Lagged Behind LDL Cholesterol Screening
4
What the 2025-2030 Dietary Guidelines Mean for Heart Health
5